Bafna Pharmaceuticals Ltd Share Price

Bafna Pharmaceuticals Ltd share price today is ₹264.21, as of 25 Aug 2026, 03:13 PM IST. The stock price moves through the trading day as buyers and sellers react to company news, sector trends, and overall market activity. For the current price and today's high and low, see the live price at the top of this page.

Bafna Pharmaceuticals Ltd market cap is ₹ 570.00 Cr.. Market capitalisation is calculated by multiplying the current share price by the total number of outstanding shares, and it shows the company's overall size in the market.

Whether to buy Bafna Pharmaceuticals Ltd now depends on your financial goals and risk appetite, and opinions on the stock are currently mixed. Key metrics as of 25 Aug 2026, 03:13 PM IST: a share price of ₹264.21, a P/E ratio of around 80.31, and Mar 2020 net profit of ₹0.32 Cr. (31.05% QoQ). Before buying, weigh the valuation against Healthcare peers, the 52-week range, debt levels, and the consistency of earnings.

Over the past 52 weeks, Bafna Pharmaceuticals Ltd has traded between a low of ₹93.59 and a high of ₹288.38. This range shows the highest and lowest prices the stock has reached in the last year, which many investors use to see where the current price stands against its recent history. A price near the 52-week high or low can signal momentum or a shift in sentiment, though it is best read alongside the company's fundamentals.

Whether Bafna Pharmaceuticals Ltd stock is a good buy depends on your financial goals and time horizon, so it will suit some investors more than others. As of 25 Aug 2026, 03:13 PM IST, the stock trades around ₹264.21 with a market capitalisation of ₹ 570.00 Cr., within a 52-week range of ₹93.59 to ₹288.38. Where the current price sits in that range, read alongside the company's fundamentals, is worth weighing against its Healthcare peers before deciding.

For a long-term view, Bafna Pharmaceuticals Ltd's business strength matters more than its day-to-day price. As of 25 Aug 2026, 03:13 PM IST, it trades around ₹264.21 with a market capitalisation of ₹ 570.00 Cr. and a P/E of 80.31, within a 52-week range of ₹93.59 to ₹288.38. Long-term investors typically look for consistent earnings growth, a durable edge in Healthcare, sound management, and a fair entry valuation, so weigh these fundamentals and your own goals before committing

Whether Bafna Pharmaceuticals Ltd is overvalued or undervalued comes down to its valuation ratios against peers and its own history. As of 25 Aug 2026, 03:13 PM IST, its P/E ratio is 80.31 and its P/B ratio is 7.37, versus a Healthcare average P/E of about 39.62. If its multiples sit above the sector average the stock may look expensive; if below, it may look attractively valued. Read these alongside earnings quality and growth outlook, since a higher multiple can be justified by faster growth.

Bafna Pharmaceuticals Ltd currently has a PE (Price-to-Earnings) ratio of 80.31 and a PB (Price-to-Book) ratio of 7.37. The PE ratio shows how much investors are paying for each rupee of the company's earnings, while the PB ratio compares the share price with the company's book value per share. Both are widely used to gauge whether a stock is reasonably valued, and they work best when compared with other companies in the same sector.